While the EGL share price has been volatile the underlying business is growing; and it helps the environment!

This stock is on track to overtake Pro Medicus to become my largest ASX portfolio position. On some days it already has!

Although overshadowed by the takeover offer, Dropsuite’s Q4 FY2024 were surprisingly strong and pleasing.

AFG shares boast a P/E ratio under 15 times, a grossed up dividend yield of over 7.4%, and potential for growth.

The Genetic Signatures (ASX: GSS) share price suffers from its lack of profitability, but the diagnostic testing company may be on the verge of substantial growth.

It is not obviously cheap but it is obviously taking market share from its competitors.

You don’t often find dividend paying micro-caps with exposure to a potential demand tailwind, and a well-aligned board.

Factors outside the company’s control will have a negative influence on profit growth in FY 2025 and FY 2026

The Fineos (ASX: FCL) share price performed strongly after a recent company presentation.

Maas Group (ASX: MGH) has just announced three acquisitions in the construction materials division… plus a share purchase plan at $4.65.

With the share price in the toilet after many years of bad results, is Experience Co stock presenting an opportunity?

I don’t have full confidence for the long term, but I do think the valuation has become attractive.

The 2024 Pro Medicus AGM showcased its phenomenal employee retention rates and reflected back on the company’s beginnings.

The Pro Medicus share price is up more than 50% in just a few months. I take a look at the PME stock valuation ahead of the AGM tomorrow.

The Catapult International (ASX: CAT) H1 FY 2025 results have pushed the Catapult share price well above $3. Is the move justified?

Xero’s half year report showed its ability to increase prices in Australia, but hinted at a more difficult competitive situation in the USA.

There was nothing much to celebrate arising from the Alcidion AGM and Q1 FY 2025 update.

Looking beyond the share prices.

Audinate (ASX: AD8) stock has dropped more than 50% from its peak 7 months ago, due to its extremely disappointing guidance.

Both multiple expansion and fundamental business growth have driven Dropsuite share price gains.